Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HMGCR | P04035 | 10/20 | 0.52 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.51 |
| ▸ | SIRT6 | Q8N6T7 | 2/20 | 0.51 |
| ▸ | ABCC3 | O15438 | 1/20 | 0.51 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.51 |
| ▸ | PGR | P06401 | 1/20 | 0.51 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.51 |
| ▸ | RXRA | P19793 | 1/20 | 0.51 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.51 |
| ▸ | CCKAR | P32238 | 1/20 | 0.51 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.51 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.51 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.51 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.51 |
| ▸ | SLC10A1 | Q14973 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14544900 | 1.00 | HMGCR (0.52) | HMGCRCYP2C9SIRT6ABCC3ABCB11 | |
| SCHEMBL4020685 | 1.00 | HMGCR (0.52) | HMGCRCYP2C9SIRT6ABCC3ABCB11 | |
| SCHEMBL4901682 | 1.00 | HMGCR (0.52) | HMGCRCYP2C9SIRT6ABCC3ABCB11 | |
| SCHEMBL4020679 | 1.00 | HMGCR (0.52) | HMGCRCYP2C9SIRT6ABCC3ABCB11 | |
| SCHEMBL9274196 | 1.00 | HMGCR (0.52) | HMGCRCYP2C9SIRT6ABCC3ABCB11 | |
| SCHEMBL16476432 | 0.92 | HMGCR (0.43) | HMGCR | |
| SCHEMBL9763505 | 0.91 | HMGCR (0.52) | HMGCR | |
| SCHEMBL1660810 | 0.91 | HMGCR (0.52) | HMGCR | |
| SCHEMBL9763539 | 0.91 | HMGCR (0.52) | HMGCR | |
| SCHEMBL5597970 | 0.91 | HMGCR (0.52) | HMGCR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080039625-A1 | Screening Methods | LAUTENS MARK | 2008-02-14 | — | — | US | claimed |
| EP-1817283-A1 | 2-SUBSTITUTED INDOLES, THEIR PRECURSORS AND NOVEL PROCESSES FOR THE PREPARATION THEREOF | Lautens, Mark (CA) | 2007-08-15 | — | — | EP | claimed |
| WO-2006047888-A1 | 2-SUBSTITUTED INDOLES, THEIR PRECURSORS AND NOVEL PROCESSES FOR THE PREPARATION THEREOF | LAUTENS MARK (CA) | 2006-05-11 | — | — | WO | claimed |
| US-20140140931-A1 | ANTIOXIDANT, NEUROPROTECTIVE AND ANTINEOPLASTIC NANOPARTICLES COMPRISING A THERAPEUTIC AGENT ON AN AMPHIPHILIC SPACER OR AN AMPHIPHILIC POLYMER | CEDARS-SINAI MEDICAL CENTER (US) | 2014-05-22 | — | — | US | disclosed |
| US-20140140931-A1 | ANTIOXIDANT, NEUROPROTECTIVE AND ANTINEOPLASTIC NANOPARTICLES COMPRISING A THERAPEUTIC AGENT ON AN AMPHIPHILIC SPACER OR AN AMPHIPHILIC POLYMER | CEDARS-SINAI MEDICAL CENTER (US) | 2014-05-22 | — | — | US | disclosed |
| WO-2013016696-A1 | ANTIOXIDANT, NEUROPROTECTIVE AND ANTINEOPLASTIC NANOPARTICLES COMPRISING A THERAPEUTIC AGENT ON AN AMPHIPHILIC SPACER OR AN AMPHIPHILIC POLYMER | CEDARS-SINAI MEDICAL CENTER (US) | 2013-01-31 | — | — | WO | disclosed |
| US-20080039625-A1 | Screening Methods | LAUTENS MARK | 2008-02-14 | — | — | US | disclosed |
| EP-1817283-A1 | 2-SUBSTITUTED INDOLES, THEIR PRECURSORS AND NOVEL PROCESSES FOR THE PREPARATION THEREOF | Lautens, Mark (CA) | 2007-08-15 | — | — | EP | disclosed |
| WO-2006047888-A1 | 2-SUBSTITUTED INDOLES, THEIR PRECURSORS AND NOVEL PROCESSES FOR THE PREPARATION THEREOF | LAUTENS MARK (CA) | 2006-05-11 | — | — | WO | disclosed |
| EP-0379917-B1 | Optically active (meth)acrylic-acid derivatives, their preparation, their polymerisation into optically active polymers and their use | BAYER AG (DE) | 1995-08-09 | — | — | EP | disclosed |
| US-5274167-A | A N-(meth)acryloyl amino acid amide | BAYER AKTIENGESELLSCHAFT (DE) | 1993-12-28 | — | — | US | disclosed |
| EP-0379917-A2 | Optically active (meth)acrylic-acid derivatives, their preparation, their polymerisation into optically active polymers and their use | BAYER AG (DE) | 1990-08-01 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080039625-A1 | Screening Methods | CBR3, ZKSCAN2, CRBN | HMGCR 980/4885CYP2C9 26/4885SIRT6 2321/4885 |
| US-20140140931-A1 | ANTIOXIDANT, NEUROPROTECTIVE AND ANTINEOPLASTIC NANOPARTICLES COMPRISING A THERAPEUTIC AGENT ON AN AMPHIPHILIC SPACER OR AN AMPHIPHILIC POLYMER | NLN, CASP12, GPX4 | HMGCR 8/4885CYP2C9 3251/4885SIRT6 2410/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.